SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?


To: afrayem onigwecher who wrote (761)1/13/2003 6:32:54 PM
From: StockDung  Respond to of 857
 
December 3, 2002 Fraudsters’ despair brings them to an all time low.

asensio.com

This past Sunday evening, December 1, 2002, I received an email titled “Penny Stock Promoters Strike Back” from an individual whom I had recently interviewed for a job opening at Asensio & Company, Inc. The email included a hyper-link to a site called asensioexposed.com. My immediate reaction was emotional. I was familiar with the content of the site. Asensio & Company’s settlement with the AMEX/NASD, Norman Murphy’s long-ago dismissed lawsuit, the allegations that we buy large positions in the stock we claim are engaged in fraudulent stock promotions, and other false and gross misrepresentations concerning Asensio & Company’s business practices were very familiar to me. They are the well-developed and highly-publicized fabrications of William A. Carter, the leader of the criminally-organized stock fraud called Hemispherx Biopharma, Inc. (AMEX: HEB) and his two long-time attorneys David Franceski and Michael Walsh. These three men are closely linked and have a 15 year history of viciously attacking any entity or individual that questions or criticizes Hemispherx. Despite my familiarity with all of the content and its source, the false, misleading, libelous and defamatory statements on the site disturbed me. After briefly scanning the site I sent a hyper-link to attorneys most familiar with the Hemispherx case, Agus & Partners, P.C. and Goldfein & Hosmer LLC, and went about my business.

We are the Wall Street pioneers of private-sector for profit investigation and reporting of stock fraud. We have been referred to by others as “indisputably the world’s foremost short seller.” We issued our first short sell recommendation on a company we considered to be worthless and entirely devoted to de-frauding investors in 1996. The company was called Diana Corporation and was listed on the New York Stock Exchange. It traded at over a $600 million market cap and was being promoted on Wall Street by the likes of Hambrecht & Quist and Neuberger Berman. Our battle with that company is now part of Wall Street folklore and is included in our book titled Sold Short: Uncovering Deception in the Markets published by John Wiley & Sons, Inc. Since then we have investigated and reported on 28 other companies we believed to be engaged in questionable or fraudulent stock schemes. All of these companies became very successful short sells. These have included very large companies, like WorldCom, Inc., Network Solutions, Inc., Winstar Communications, Inc. and VeriSign, Inc. and a few penny-stock frauds that were momentarily large enough for us to trade like the tiny criminally-organized Hemispherx.

In the past, an unfortunate by-product of our short-selling has been litigation. We have never paid a penny to settle any lawsuits and have won all our legal battles. All of the lawsuits were concocted by promoters seeking to protect their interests. All, except the two Hemispherx cases, were dismissed or settled before trial. We won by jury verdicts against Hemispherx in both cases. Our short selling business has evolved and grown, and is currently free of any litigation. We and our clients have grown while the over-the-counter stock market’s extra-ordinary drops have greatly reduced a fraudulent stock promoters’ ability to achieve market valuations and liquidity levels that are sufficiently large to merit attention.

Shortly after being made aware of the site, and forwarding the link to two of our attorneys, I decided not to proceed against its owners. Defamation law is time consuming and expensive. The outcome of any litigation is uncertain. Even discovering and serving who is responsible and getting the web-host and domain name register to eliminate the site will require time and money best spent on other activities.

After making this decision I have received calls and emails from our friends and colleagues. All of them are angry and asked of my plans. Each contact evoked my own first emotional reaction. But they did not change my opinion. Our reputation remains impeccable. Asensio Brokerage Services, Inc. is perhaps the only Wall Street firm that has never received a single customer complaint. Our research has been extraordinarily profitable. Our book was critically acclaimed (Ludwig von Mises Institute article titled “Stock Market Scams”). We have been the subject of news stories and have appeared in public and private broadcast and cable television news programs, and have been the subject of numerous major front page and cover news stories in most of the major business periodicals. If there are members of the investment community or the public at large who care to learn about Asensio & Company there are far less biased and dubious sources of information than “asensioexposed.”



Back to Main Menu



To: afrayem onigwecher who wrote (761)2/7/2003 2:59:23 PM
From: StockDung  Respond to of 857
 
AN OLD PENNY STOCK TRICK. PAY A FRAUD ANALYST TO WRITE A REPORT ON YOUR COMPANY THEN CALL IT RESEARCH. WHAT A BUNCH OF ODD-LOT PIKERS!!

Hemispherx Announces Taglich Brothers Release of Updated Research Report

PHILADELPHIA, Jan. 24 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (AMEX:HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today the issuance on January 22, 2003 by Taglich Brothers an update to their research report dated September 24, 2002.

Interested parties may view the updated report on Taglich Brothers website at www.TaglichBrothers.com.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information, on Hemispherx, please visit the company's Web site at hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. By publishing this press release, the Company in no way endorses any of the factual recitals or conclusions contained in the subject research report by Taglich Brothers. The Company refers all readers to its publicly filed information as well as its website for base reference.

SOURCE Hemispherx Biopharma, Inc.

CO: Hemispherx Biopharma, Inc.; Taglich Brothers

ST: Pennsylvania

SU: SVY

prnewswire.com

01/24/2003 09:01 EST



To: afrayem onigwecher who wrote (761)2/7/2003 3:02:33 PM
From: StockDung  Respond to of 857
 
FACTS ARE TAGLICH DOES NOT EVEN OWN THE STOCK. HA HA HA!! Price Target: $25.00 ON A STOCK THEY DONT EVEN OWN CURRENTLY TRADING AT $1.75.

WHAT A FRIGGIN JOKE


The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to change in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is not a market maker and does not sell to or buy from customers on a principal basis. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. Currently, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned above. Taglich Brothers, Inc., does not currently have an Investment Banking relationship with the company and was not a manager or co-manager of any offering for the company within the last three years. The company pays Taglich Brothers, Inc. a monthly fee for the creation and dissemination of research reports.


taglichbrothers.com

Hemispherx BioPharma

--------------------------------------------------------------------------------
Analyst: Andre Garnet
Taglich Rating: Speculative Buy
Price Target: $25.00
Time Horizon: 36 Months
Rating Established: January 22, 2003
Price When Established: $2.00
--------------------------------------------------------------------------------


What's New
Updated Research Report (Dated January 22, 2003)

Company Description
Hemispherx BioPharma, Inc. (HEB) is focused on the research and development of RNA drugs. The Company’s lead product, ampligen, is currently undergoing clinical trials for the treatment of chronic fatigue syndrome and HIV/AIDS and has shown extremely promising interim results.
Taglich Research Reports
Updated Research Report (Dated September 25, 2002)
Updated Research Report (Dated June 19, 2002)
Initial Research Report (Dated April 15, 2002)

--------------------------------------------------------------------------------
All Research Reports are in Adobe Acrobat format.
(for the latest Adobe Acrobat reader click here)
--------------------------------------------------------------------------------

The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to change in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is not a market maker and does not sell to or buy from customers on a principal basis. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. Currently, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned above. Taglich Brothers, Inc., does not currently have an Investment Banking relationship with the company and was not a manager or co-manager of any offering for the company within the last three years. The company pays Taglich Brothers, Inc. a monthly fee for the creation and dissemination of research reports.

Send this Page to a friend
To send this page to a friend, just fill out the form below and



To: afrayem onigwecher who wrote (761)3/20/2003 7:46:58 PM
From: StockDung  Respond to of 857
 
OFFSHORE FUND DIRECTOR ACCUSED OF BRIBING FBI AGENT TIED TO HEMISPHERIX

HEMISPHERIX SEC FILING 4/11/1997

Michael Lauer(8) 30,000 30,000
Lancer Offshore, Inc.(8) 345,000 345,000
Lancer Partners, LP(8) 325,000 325,000
Lancer Voyage Fund(8) 50,000 50,000
(8) Represents shares of Common Stock underlying Series E Preferred.
-----------------------------------------

LANCER OFF IRISH STOCK EXCHANGE

By CHRISTOPHER BYRON
--------------------------------------------------------------------------------

March 20, 2003 --
The bad news keeps coming for Park Avenue's teetering Lancer hedge fund empire.

Yesterday the company disclosed that its flagship operation, the Lancer Offshore Fund, has been suspended from listing on the Irish Stock Exchange.

The news is the latest setback for the once high-flying Lancer family of funds, which said last autumn it had more than $1 billion of assets under management.

Now the group, headed by an ex-Wall Street analyst Michael Lauer, is struggling to meet redemption demands from investors worried about the quality of Lancer's audits and the stocks in its portfolios.

Lancer's problems began to mount last summer after the U.S. Department of Justice charged a man identified as a Lancer managing director named Bruce D. Cowen with conspiring to bribe an FBI undercover agent, using stock held in a Lancer portfolio.

SEC filings show that Cowen, who is currently under a five-year SEC ban from serving as an officer or director of a U.S. public company, has been a joint investor with Lancer in at least 10 different companies.

Lancer and Lauer are now suing The Post for its coverage of the matter.

According to yesterday's press release, issued by the Irish Stock Exchange, where many offshore hedge funds are quoted, the Lancer suspension followed an announcement by Lancer in early January that Lancer Offshore would cease redeeming its shares for cash and instead issue investors shares in a new fund containing assets identical to the existing fund.

The press release said the arrangement "may not comply with the requirements of the Irish Stock Exchange," and that the Lancer Offshore listing was being suspended until the matter could be resolved.

The heart of the Lancer problem appears to be the ultra-generous valuations given by the company to the stocks in its portfolio, the bulk of which look to be illiquid penny stocks.

One such company, Biometrics Security Technology Inc., is now trading on the OTC Bulletin Board for $3 - giving the company a market value of $314 million - even though 97 percent of its stock is held by Lancer.

The company's latest address is listed in a Dec. 20, 2002, SEC filing as Suite 305W of 1900 Corporate Park, Boca Raton, Fla., and the company's president as Laurence S. Isaacson.

But two other companies in which SEC filings show Lancer to have recently held 97 percent stakes - Lionshare Corp., and Centrack International Inc. - use the same address and phone number as Biometric.

What's more, the same people seem to shuffle back and forth through all three. Thus, SEC filings identify Isaacson (the current CEO of Biometric) as the former CEO of Centrack.

Other filings show an individual named George Weast as the former CEO of Centrack as well as the CEO of Lionshare.

Last month, Weast stepped aside to make room for the current CFO of Biometric, Jeff Baracos, to succeed him as CEO of Lionshare.

Isaacson himself is listed in SEC filings as not only the past or present head of both Biometric and Centrack, but as CEO of Thornhill Group Inc., which also uses the 1900 Corporate Park address.

Filings with the National Association of Securities Dealers list Thornhill as a NASD broker/dealer.

For more information and headlines on this company



To: afrayem onigwecher who wrote (761)3/22/2003 12:54:54 PM
From: StockDung  Read Replies (1) | Respond to of 857
 
Smallpox Treatment or Snake Oil? 
wired.com

By Kristen Philipkoski  
02:00 AM Nov. 19, 2001 PT

With bioterrorism threats snowballing in the United States, one biotech company says it may be able to come to the rescue should an attack occur.


But skeptics abound. They say the company, Hemispherx Biopharma, and its leading drug candidate are at best questionable and at worst a fraud.

Hemispherx CEO William Carter, one of the earliest researchers on interferon therapies -- now widely used to treat some viruses and cancers -- is used to the criticism. He vigorously defends his company and its product.

"Our new technology, called nucleic acid technology, will circumvent what the smallpox virus does to destroy and to kill cells," Carter said. "(It) goes directly into the cell and activates from within as opposed to outside."

The "new technology" Carter refers to -- Ampligen -- is actually 25 years old but has never been approved by the FDA and has been disappointing in clinical trials. That's why some researchers dismiss his claims out of hand.

"This company has a long history of making impressive claims, which unfortunately don't always pan out," said Steven Block, a professor of biological sciences and applied physics at Stanford University. "That's not to say that they never will, but a certain amount of caution is called for here."

Carter, who founded his company (HEB) 30 years ago and whose only potential product remains Ampligen, recently said in an interview with WallStreetReporter.com that Ampligen could also treat Ebola.

Skeptical scientists point out that only two human studies, showing unimpressive results, have been published on Ampligen.

"I doubt it will ever be marketed, to be frank," said Joseph Guglielmo, an infectious diseases expert and vice chairman of a clinical pharmacy at the University of California at San Francisco.

Hemispherx (HEB) said earlier this month that it will announce the results of its most recent AIDS trials at an upcoming World Health Organization meeting in Europe. It didn't indicate a date or location for the meeting.

Carter admits the drug has never been tested for smallpox treatment. But he said, "Based on rational drug design, it would have a real chance to be effective."

Carter said Ampligen could be a good choice for people who are not candidates for the smallpox vaccine, such as pregnant women, patients undergoing chemotherapy and people with kidney transplants.

In a few days, Carter said, Hemispherx will submit a "major clinical protocol" to the government, proposing a program to treat those people with Ampligen should they contract smallpox.

Ampligen is a "mismatched RNA double strand," something that researchers have been studying since 1976. The drug works, Carter said, because it stimulates interferon. Interferon is made of proteins that boost the human body's first lines of immune defense.

Researchers not affiliated with Hemishpherx recently completed a laboratory (non-human) study that showed Ampligen combined with 14 anti-HIV drugs boosted the effectiveness of many of the drugs. The results are promising, but how Amipligen will work in humans still remains to be seen, said W. Edward Robinson, an associate professor of pathology and infectious diseases in the department of internal medicine at the University of California at Irvine, one of the authors of the study.

He also said that claims the drug could work on smallpox might be unfounded. "As far as I know there's absolutely no data to support that," Robinson said. "However, because of the way it reportedly works ... it makes sense that it could work."Smallpox claimed more than 300 million lives before 1978 -- more than any other infectious disease -- but was considered eradicated in 1980. It spreads through coughing, sneezing or physical contact and kills about 30 percent of those infected within 15 to 20 days. The disease causes painful, pus-filled boils all over the body. The United States maintains a stockpile of about 15.4 million doses of the smallpox vaccine, which is only enough to vaccinate about 7 percent of the population. The government has recently begun studies to see if that supply can be diluted and expanded. Hemispherx researchers believe Amipligen could treat AIDS, hepatitis, chronic fatigue syndrome and other diseases. Researchers, however, say no studies have led anyone to believe the drug could successfully treat any of these diseases, let alone smallpox. "The activity has never been very impressive," said Eric Wickstrom, a professor of microbiology and immunology at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia."This hasn't been the bombshell drug that was hoped for a long time ago," said Dr. William Shearer, a professor of pediatrics and immunology at the Baylor College of Medicine in Houston. Still, investors have had faith in Hemispherx and its only product. Even though the company brought in, just $788,000 in revenue for all of 2000, it has a market cap of about $113 million. The company's most vocal critic is Manuel Asensio, an investment banker who "short sells" stock. He launched a campaign against the company in 1998.Asensio has historically targeted companies he believes are misrepresenting their business to investors. At least three companies have been de-listed in the wake of his efforts. The duel between Asensio and Hemispherx was given front page coverage by The Wall Street Journal in June 2000. The feud has escalated from Asensio's accusations of fraud to Hemispherx suing Asensio for illegal short-selling, defamation and interference with business practices. Asensio said fighting the suit has cost him $4 million so far. Asensio said the Securities and Exchange Commission is investigating Hemispherx. SEC officials declined to confirm or deny the investigation.



To: afrayem onigwecher who wrote (761)7/21/2003 8:28:36 AM
From: StockDung  Respond to of 857
 
.LANCER'S MOVIE MAGIC

By CHRISTOPHER BYRON Rider Strong in "Cabin Fever"

July 21, 2003 -- IF you're looking for an instructive way to spend an evening this summer, check out a movie bearing the name "The Secret Lives of Dentists." Or how about a forgettable little celluloid event entitled "Cabin Fever"? And toward the end of the year, try to catch something called "Blizzard."

Just pay attention to the credits.

If you do, you'll begin to see why I've been pounding the table over the activities of a collapsed Park Avenue hedge fund family known as the Lancer Group. The Group - or at least, let us say, certain people who work for it - made those movies using money that came, in a distinctly roundabout way, from Lancer's own portfolio.

For years now, the ghastly Lancer Group operation - hiding in plain view in an elegant Park Avenue high-rise in mid-town - has been separating the well-heeled and gullible from their money by murmuring comforting phrases like "small cap growth opportunity" in their ears.

Too bad that what they were really describing, in a startling number of cases, were worthless penny stocks controlled by professional swindlers and fraudsters.

Add to that the sheer brazenness of the Lancer bunch - strutting around Hollywood drenched in the aromas of fast money - and you have what the Lancer Group was really all about from Day 1: The out-of-control ego trip of a one-time Wall Street analyst named Michael Lauer, who thought he could hold his own in the penny stock market, only to wind up in the crosshairs of the Feds for financing many of its worst excesses.

document.write('');

NOW, with the SEC's seizure of Lancer's books and records, is it possible to begin unraveling the Group's mysterious Hollywood connection, in which a defunct Tinseltown penny-stock company named Total Film Group Inc. devoured at least $15 million during the film company's short and lurid life, and may have been used to hide the theft of up to $18 million more.

It isn't yet possible to say for sure just how much Lancer money was ultimately pounded down the Total Film Group rat hole, because the books of both entities look to be wildly in conflict with each other.

Between March and December 2002, for example, the monthly portfolio statements of the Lancer Group's various hedge funds show roughly $18 million of loan transactions between the funds and Total Film Group.

But Jeffrey Hoffman, who served as Total Film's chief executive officer during the period in question - until officially resigning on June 30 of this year - insisted to me last week that he knew absolutely nothing about the transactions and that, from January of last year onward, Total Film Group was a defunct shell company that conducted no business activities.

Hoffman sounded genuinely baffled as to why the Lancer portfolios seem to show Total Film Group having received $500,000 in a loan from Lancer during June 2002 - creating a total loan outstanding of $4.325 million, which is abruptly reduced in July by 88 percent, to a balance of just $500,000. Hoffman insisted categorically that no such transactions occurred.

The Securities and Exchange Commission has finally done the right thing and pronounced the Lancer Group a top-to-bottom swindle machine, and a receiver has been appointed to recover what it can of the Group's assets.

But as the fog enveloping the accounts of Total Film Group shows, the salvage effort may not yield very much. Cash from the Group's fat-cat investors was really the only asset of genuine value the Group ever had - and nearly all of that has now disappeared into penny-stock trash like Total Film Group.

TOTAL Film came into being in 1997, when an organized-crime thug and ex-con securities fraudster named Abraham Salaman bolted together a dormant penny-stock company in the hair care business with a privately held Nevada company he controlled called Total Media Inc. - then brought in Lauer to pump the thing full of money.

Salaman has been a key investment partner of Lauer from almost the founding of the Lancer Group in 1994, pushing flaky and doomed penny-stock promotions ranging from walk-in centers for schizophrenics to a plan to launch a TV network on the Internet.

With each of his deals, the script has been the same: Lauer brings in the money, the stock price soars, then the business collapses, the stock crashes, and millions of dollars simply vanish.

And that is what happened in the case of Total Media. The merged entity was renamed Total Film Group Inc., and Lauer quickly began pouring in Lancer cash in return for Total Film shares. And, predictably enough, by the spring of 2001 the company's revenues were tumbling, its overhead was soaring, and its losses were exploding.

So Lauer replaced Total Film's CEO, a South African stock promoter named Gerald Green, with the aforementioned Jeffrey Hoffman, who immediately fired 75 percent of the company's employees and began looking for what to do next.

What Hoffman wanted to do was make movies. And even though he was still the CEO of Total Film Group, he decided to get in the game by setting up his own private movie production company, called Black Sky Entertainment, which he did in October 2001 - a move that in effect made him a competitor with himself.

But that didn't stop Lauer - who was still carrying the defunct Total Film Group on his hedge fund's books as an asset worth more than $50 million - from pushing Lancer cash in Hoffman's direction to get in on the new Tinseltown action.

Though Hoffman's partner at Black Sky, Glenn Weisberger, said to me last week that Black Sky has so far borrowed only about $1.25 million from Lancer, the most recent portfolios for the hedge funds themselves, from April 2003, show loans to Black Sky of nearly $2.9 million - yet another case of Lancer's books showing multimillion-dollar loans that the Hoffman folks say they've never received.

In any case, the money they did receive was apparently enough that Hoffman and Black Sky have been able to help make at least one movie - the aforementioned "Cabin Fever" (about teenagers who fight some sort of flesh-eating virus). For the moment, Lauer is listed as "co-producer" on the film, but Hoffman says the Lancer man has asked to have his name removed.

MEANWHILE, Lauer and his crew have been busy using Lancer bucks to elevate themselves in La-La Land in yet another way. Since spring 2002, Lancer has been lending money, which now appears to total nearly $4 million, to a Canadian movie company called Knightscove Entertainment.

Those loans have coincided with the release of a movie called "Virginia's Run" and with the filming of a second film, "Blizzard," set for release this December. Both films were co-produced by Knightscove in cooperation with a New York outfit called Holedigger Films, which is owned by two of Lauer's underlings at Lancer: David Newman and Martin Garvey.

Finally, if you want to see the names of virtually the entire employment roster of the Lancer bunch scroll down the screen, check out the "executive producer" screen credits for yet another Holedigger release, "The Secret Lives of Dentists." Garvey and Newman are there, as is Lauer himself. And there's even an "executive producer" screen credit for a Lauer flunky named Bruce Cowen, now awaiting trial in Miami for allegedly attempting to bribe an undercover FBI agent with penny-stock shares in the Lancer portfolio.

How much more of this sort of thing may have gone on behind the drawn curtains of the Lancer Group is hard to say, at least for now. But investigators are likely to keep pressing for answers as to what really happened to $1 billion worth of hedge-fund money that was here one minute then gone the next. In time, I suspect we'll all know.

* Please send e-mail to: cbyron@nypost.com